SCHEDULE: Citadel Entities Disclose 5.5% Stake in Core Scientific
Beneficial Ownership Disclosure
Citadel Securities GP LLC, Citadel Securities Group LP, and Kenneth Griffin have disclosed a 5.5% beneficial ownership stake in Core Scientific, Inc. common stock.
Summary
- Citadel Securities GP LLC, Citadel Securities Group LP, and Kenneth Griffin each beneficially own 17,185,727 shares of Core Scientific, Inc. common stock, representing 5.5% of the class.
- Citadel Securities LLC beneficially owns 14,020,517 shares, which constitutes 4.5% of the outstanding shares.
- Citadel Advisors LLC, Citadel Advisors Holdings LP, and Citadel GP LLC each beneficially own 0 shares.
- The percentages are based on 310,064,165 shares outstanding, comprised of 310,061,300 shares as of October 20, 2025, and 2,865 shares issuable upon conversion of certain warrants.
- The reporting persons disclaim that the securities were acquired or are held for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: The filing is a standard disclosure of beneficial ownership, indicating a neutral sentiment as it primarily provides factual information without expressing positive or negative outlooks or operational changes.
Future Outlook
NA
Industry Context
This filing indicates a significant passive investment by Citadel entities in Core Scientific, a company operating in the digital asset mining and infrastructure sector. Such disclosures are common for large institutional investors taking positions in publicly traded companies, reflecting their investment strategies rather than direct operational involvement or strategic partnership.
Stakeholder Impact
- Shareholders: Increased transparency regarding significant institutional ownership, potentially signaling confidence from a major financial player, though the filing explicitly states the shares are not held for control purposes.
Key Dates
| Date | Description |
|---|---|
| 2023-10-13 | Date of filing of power of attorney for Seth Levy on behalf of Kenneth Griffin, attached to a Schedule 13G for Allakos Inc. by Citadel Advisors LLC. |
| 2025-10-20 | Date for which 310,061,300 shares outstanding were reported in the issuer's Form 10-Q. |
| 2025-10-24 | Date the issuer's Form 10-Q was filed with the SEC. |
| 2025-12-03 | Date of event which requires the filing of this statement. |
| 2025-12-10 | Date of filing of this Schedule 13G statement and the date for which all reported shares for the holdings of the reporting persons are as of the opening of the market. |
Keywords
Core Scientific, Citadel Securities, Kenneth Griffin, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Ownership, Equity Stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.